CL vs EMR

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 23, 2026

CL

23.5
AI Score
VS
EMR Wins

EMR

49.9
AI Score

Investment Advisor Scores

CL

24score
Recommendation
SELL

EMR

50score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CL EMR Winner
Revenue 10.69B 13.78B EMR
Net Income 1.34B 1.94B EMR
Net Margin 12.5% 14.1% EMR
ROE 567.4% 9.5% CL
ROA 8.0% 4.6% CL
Total Assets 16.79B 42.21B EMR
Debt/Equity 33.15 0.37 EMR
Current Ratio 1.03 0.90 CL

Relative Price Performance (Last 90 Days)

CL 1M: +13.3% · 3M: +7.3% EMR 1M: +3.7% · 3M: +8.3%

Current Technical Phase

CL

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 74

RSI (14): 74.1 · Price: $97.39

EMR

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.6% over 20 days), RSI 53

RSI (14): 53.5 · Price: $160.29

Fundamentals Snapshot

Metric CL EMR
Market Cap — —
Forward P/E 23.8 22.0
Trailing P/E 37.2 35.7
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.6% 0.5%
Operating Margin 0.2% 0.3%
EPS 2.51 4.57
Dividend Yield 0.02% 0.01%

Frequently Asked Questions

Based on our detailed analysis, EMR is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.